REG - Haleon PLC - Holding(s) in Company

HALEONAnnouncement

22/03/2024 11:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240322:nRSV9904Ha&default-theme=true

RNS Number : 9904H  Haleon PLC  22 March 2024

22 March 2024

HALEON PLC

("Haleon" or "the Company") 

 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BMX86B70

Issuer Name

HALEON PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Pfizer Inc.

City of registered office (if applicable)

New York

Country of registered office (if applicable)

United States of America

4. Details of the shareholder

 Name                       City of registered office  Country of registered office
 Guaranty Nominees Limited  London                     United Kingdom
 BofA Securities, Inc.      Wilmington, Delaware       United States of America

5. Date on which the threshold was crossed or reached

21-Mar-2024

6. Date on which Issuer notified

21-Mar-2024

7. Total positions of person(s) subject to the notification obligation

                                                                            % of voting rights attached to shares (total of 8.A)  % of voting rights through financial instruments (total of 8.B 1 + 8.B 2)  Total of both in % (8.A + 8.B)  Total number of voting rights held in issuer
 Resulting situation on the date on which threshold was crossed or reached  22.580000                                             0.000000                                                                   22.580000                       2062236079
 Position of previous notification (if applicable)                          32.000000                                             0.000000                                                                   32.000000

8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached

8A. Voting rights attached to shares

 Class/Type of shares ISIN code(if possible)  Number of direct voting rights (DTR5.1)  Number of indirect voting rights (DTR5.2.1)  % of direct voting rights (DTR5.1)  % of indirect voting rights (DTR5.2.1)
 Ordinary Shares GB00BMX86B70                                                          1667778175                                                                       18.260000
 Restricted ADSs                                                                       394457904                                                                        4.320000
 Sub Total 8.A                                2062236079                                                                            22.580000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

 Type of financial instrument  Expiration date  Exercise/conversion period  Number of voting rights that may be acquired if the instrument is  % of voting rights
                                                                            exercised/converted

 Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to
(DTR5.3.1R.(1) (b))

 Type of financial instrument  Expiration date  Exercise/conversion period  Physical or cash settlement  Number of voting rights  % of voting rights

 Sub Total 8.B2

9. Information in relation to the person subject to the notification
obligation

1. Person subject to the notification obligation is not controlled by any
natural person or legal entity and does not control any other undertaking(s)
holding directly or indirectly an interest in the (underlying) issuer.

 Ultimate controlling person  Name of controlled undertaking  % of voting rights if it equals or is higher than the notifiable threshold  % of voting rights through financial instruments if it equals or is higher  Total of both if it equals or is higher than the notifiable threshold
                                                                                                                                          than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

This notification relates to the sale by Pfizer Inc. ("Pfizer") of a portion
of its interest in Haleon plc ("Haleon").

 

Pfizer sold 594,000,000 Haleon ordinary shares and 196,554,820 ordinary shares
in the form of American depositary shares, each representing two ordinary
shares ("ADSs") pursuant to a global offer. In connection with the global
offer, Haleon repurchased 102,272,727 ordinary shares from Pfizer in
accordance with the terms of a share purchase deed between Haleon and Pfizer
dated 11 September 2023 and approved by Haleon's shareholders at its annual
general meeting on 20 April 2023.

These calculations are based on an issued share capital of Haleon of
9,132,301,104 ordinary shares, following cancellation of the 102,272,727
ordinary shares repurchased from Pfizer, as communicated by Haleon in their
announcement on total voting rights and capital dated 21 March 2024.

Pfizer holds its ordinary shares in Haleon through (i) BofA Securities, Inc.,
and (ii) Guaranty Nominees Limited (in respect of the ADSs), which hold the
legal title to those shares on Pfizer's behalf.

12. Date of Completion

21-Mar-2024

13. Place Of Completion

New York, USA

 

 

Amanda Mellor, Company Secretary

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  HOLUUUARSUUOUAR